Summary
This report provides an overview of the pipeline landscape for dermatological burns, scars and ulcers. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pressure ulcers, venous leg ulcers, burns and scars, and features dormant and discontinued products.
A pressure ulcer is an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition. There are six products in development for this indication.
Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of a finger when pressed (known as pitting edema), discoloration and darkening of the skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make the leg feel hard (known as lipodermatosclerosis), and small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche). There are 14 products in development for this indication.
A burn refers to damage to the body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, which increases with each degree of burn, red and swollen skin, blisters, and charred and blackened skin. Treatment includes antibiotics and pain relievers. There are 32 products in development for this indication.
A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red-to-purple fibrous tissue that over time usually becomes flatter and lighter in color. There are 20 products in development for this indication.
Molecular targets acted on by products in development for dermatological burns, scars and ulcers include integrins, interleukins and growth factors. Companies operating in this pipeline space include MediWound, Aegle Therapeutics and NovaLead Pharma.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
'
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Dermatological Burns, Scars and Ulcers Report Coverage 8
2.2 Pressure Ulcers - Overview 8
2.3 Venous Leg Ulcers (Crural Ulcer) - Overview 8
2.4 Burns - Overview 8
2.5 Scar - Overview 8
3 Therapeutics Development 9
3.1 Pressure Ulcers 9
3.2 Venous Leg Ulcers (Crural Ulcer) 11
3.3 Burns 15
3.4 Scar 21
4 Therapeutics Assessment 26
4.1 Pressure Ulcers 26
4.2 Venous Leg Ulcers (Crural Ulcer) 29
4.3 Burns 35
4.4 Scar 43
5 Companies Involved in Therapeutics Development 49
5.1 Pressure Ulcers 49
5.2 Venous Leg Ulcers (Crural Ulcer) 51
5.3 Burns 56
5.4 Scar 62
6 Dormant Projects 69
6.1 Pressure Ulcers 69
6.2 Venous Leg Ulcers (Crural Ulcer) 69
6.3 Burns 71
6.4 Scar 73
7 Discontinued Products 74
7.1 Pressure Ulcers 74
7.2 Venous Leg Ulcers (Crural Ulcer) 74
7.3 Burns 75
7.4 Scar 75
8 Product Development Milestones 76
8.1 Venous Leg Ulcers (Crural Ulcer) 76
8.2 Burns 86
8.3 Scar 100
9 Appendix 113
9.1 Methodology 113
9.2 Coverage 113
9.3 Secondary Research 113
9.4 Primary Research 113
9.5 Expert Panel Validation 113
9.6 Contact Us 114
9.7 Disclaimer 114
1.1 List of Tables
Table 1: Number of Products under Development for Pressure Ulcers 9
Table 2: Number of Products under Development by Companies, Pressure Ulcers 10
Table 3: Products under Development by Companies, Pressure Ulcers 11
Table 4: Number of Products under Development for Venous Leg Ulcers (Crural Ulcer) 12
Table 5: Number of Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer) 13
Table 6: Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer) 14
Table 7: Number of Products under Development for Burns 15
Table 8: Number of Products under Development by Companies, Burns 17
Table 9: Number of Products under Development by Universities/Institutes, Burns 18
Table 10: Products under Development by Companies, Burns 19
Table 11: Products under Development by Universities/Institutes, Burns 20
Table 12: Number of Products under Development for Scar 21
Table 13: Number of Products under Development by Companies, Scar 22
Table 14: Number of Products under Development by Universities/Institutes, Scar 23
Table 15: Products under Development by Companies, Scar 24
Table 16: Products under Development by Universities/Institutes, Scar 25
Table 17: Number of Products by Stage and Target, Pressure Ulcers 26
Table 18: Number of Products by Stage and Mechanism of Action, Pressure Ulcers 26
Table 19: Number of Products by Stage and Route of Administration, Pressure Ulcers 27
Table 20: Number of Products by Stage and Molecule Type, Pressure Ulcers 29
Table 21: Number of Products by Stage and Target, Venous Leg Ulcers (Crural Ulcer) 30
Table 22: Number of Products by Stage and Mechanism of Action, Venous Leg Ulcers (Crural Ulcer) 32
Table 23: Number of Products by Stage and Route of Administration, Venous Leg Ulcers (Crural Ulcer) 33
Table 24: Number of Products by Stage and Molecule Type, Venous Leg Ulcers (Crural Ulcer) 35
Table 25: Number of Products by Stage and Target, Burns 37
Table 26: Number of Products by Stage and Mechanism of Action, Burns 39
Table 27: Number of Products by Stage and Route of Administration, Burns 41
Table 28: Number of Products by Stage and Molecule Type, Burns 42
Table 29: Number of Products by Stage and Target, Scar 44
Table 30: Number of Products by Stage and Mechanism of Action, Scar 45
Table 31: Number of Products by Stage and Route of Administration, Scar 47
Table 32: Number of Products by Stage and Molecule Type, Scar 48
Table 33: Pressure Ulcers - Pipeline by EyeGene Inc 49
Table 34: Pressure Ulcers - Pipeline by Izun Pharmaceuticals Corp 49
Table 35: Pressure Ulcers - Pipeline by MimeTech Srl 50
Table 36: Pressure Ulcers - Pipeline by NovaLead Pharma Pvt Ltd 50
Table 37: Venous Leg Ulcers (Crural Ulcer) - Pipeline by CardioVascular BioTherapeutics Inc 51
Table 38: Venous Leg Ulcers (Crural Ulcer) - Pipeline by CytoTools AG 51
Table 39: Venous Leg Ulcers (Crural Ulcer) - Pipeline by Daval International Ltd 52
Table 40: Venous Leg Ulcers (Crural Ulcer) - Pipeline by Factor Therapeutics Ltd 52
Table 41: Venous Leg Ulcers (Crural Ulcer) - Pipeline by FirstString Research Inc 53
Table 42: Venous Leg Ulcers (Crural Ulcer) - Pipeline by GangaGen Inc 53
Table 43: Venous Leg Ulcers (Crural Ulcer) - Pipeline by MallInckrodt Plc 54
Table 44: Venous Leg Ulcers (Crural Ulcer) - Pipeline by MediWound Ltd 54
Table 45: Venous Leg Ulcers (Crural Ulcer) - Pipeline by NovaLead Pharma Pvt Ltd 55
Table 46: Venous Leg Ulcers (Crural Ulcer) - Pipeline by Promore Pharma AB 55
Table 47: Burns - Pipeline by AlgiPharma AS 56
Table 48: Burns - Pipeline by Alliance Pharma Plc 56
Table 49: Burns - Pipeline by Amarantus Bioscience Holdings Inc 57
Table 50: Burns - Pipeline by CFM Pharma Holding BV 57
Table 51: Burns - Pipeline by Destiny Pharma Plc 58
Table 52: Burns - Pipeline by Energenesis Biomedical Co Ltd 58
Table 53: Burns - Pipeline by Madam Therapeutics BV 59
Table 54: Burns - Pipeline by MallInckrodt Plc 59
Table 55: Burns - Pipeline by MediWound Ltd 60
Table 56: Burns - Pipeline by Phagelux Inc 60
Table 57: Burns - Pipeline by Se-cure Pharmaceuticals Ltd 61
Table 58: Burns - Pipeline by Therapure Biopharma Inc 61
Table 59: Burns - Pipeline by USV Pvt Ltd 62
Table 60: Scar - Pipeline by Abzena Plc 62
1.2 List of Figures
Figure 1: Number of Products under Development for Pressure Ulcers 9
Figure 2: Number of Products under Development by Companies, Pressure Ulcers 10
Figure 3: Number of Products under Development for Venous Leg Ulcers (Crural Ulcer) 11
Figure 4: Number of Products under Development by Companies, Venous Leg Ulcers (Crural Ulcer) 12
Figure 5: Number of Products under Development for Burns 15
Figure 6: Number of Products under Development by Companies, Burns 16
Figure 7: Number of Products under Development for Scar 21
Figure 8: Number of Products under Development by Companies, Scar 22
Figure 9: Number of Products under Development by Universities/Institutes, Scar 23
Figure 10: Number of Products by Routes of Administration, Pressure Ulcers 26
Figure 11: Number of Products by Stage and Routes of Administration, Pressure Ulcers 27
Figure 12: Number of Products by Molecule Types, Pressure Ulcers 28
Figure 13: Number of Products by Stage and Molecule Types, Pressure Ulcers 28
Figure 14: Number of Products by Top 10 Targets, Venous Leg Ulcers (Crural Ulcer) 29
Figure 15: Number of Products by Stage and Top 10 Targets, Venous Leg Ulcers (Crural Ulcer) 30
Figure 16: Number of Products by Top 10 Mechanism of Actions, Venous Leg Ulcers (Crural Ulcer) 31
Figure 17: Number of Products by Stage and Top 10 Mechanism of Actions, Venous Leg Ulcers (Crural Ulcer) 31
Figure 18: Number of Products by Routes of Administration, Venous Leg Ulcers (Crural Ulcer) 32
Figure 19: Number of Products by Stage and Routes of Administration, Venous Leg Ulcers (Crural Ulcer) 33
Figure 20: Number of Products by Molecule Types, Venous Leg Ulcers (Crural Ulcer) 34
Figure 21: Number of Products by Stage and Molecule Types, Venous Leg Ulcers (Crural Ulcer) 34
Figure 22: Number of Products by Top 10 Targets, Burns 35
Figure 23: Number of Products by Stage and Top 10 Targets, Burns 36
Figure 24: Number of Products by Top 10 Mechanism of Actions, Burns 38
Figure 25: Number of Products by Stage and Top 10 Mechanism of Actions, Burns 38
Figure 26: Number of Products by Routes of Administration, Burns 40
Figure 27: Number of Products by Stage and Routes of Administration, Burns 40
Figure 28: Number of Products by Molecule Types, Burns 41
Figure 29: Number of Products by Stage and Molecule Types, Burns 42
Figure 30: Number of Products by Top 10 Targets, Scar 43
Figure 31: Number of Products by Stage and Top 10 Targets, Scar 43
Figure 32: Number of Products by Top 10 Mechanism of Actions, Scar 44
Figure 33: Number of Products by Stage and Top 10 Mechanism of Actions, Scar 45
Figure 34: Number of Products by Routes of Administration, Scar 46
Figure 35: Number of Products by Stage and Routes of Administration, Scar 46
Figure 36: Number of Products by Molecule Types, Scar 47
Figure 37: Number of Products by Stage and Molecule Types, Scar 48
